Invention Grant
- Patent Title: FGF21 compound / GLP-1R agonist combinations with optimized activity ratio
-
Application No.: US15851963Application Date: 2017-12-22
-
Publication No.: US10583174B2Publication Date: 2020-03-10
- Inventor: Britta Göbel , Mark Sommerfeld , Oliver Boscheinen , Thomas Langer , Christine Rudolph , Andreas Evers
- Applicant: SANOFI
- Applicant Address: FR Paris
- Assignee: SANOFI
- Current Assignee: SANOFI
- Current Assignee Address: FR Paris
- Agency: Lathrop GPM LLP
- Agent James H. Velema, Esq.
- Priority: EP16306776 20161222
- Main IPC: A61K38/26
- IPC: A61K38/26 ; C07K14/50 ; A61K38/18 ; C07K14/605 ; A61K47/60 ; A61P3/10 ; A61K38/39 ; C07K19/00
Abstract:
The present invention relates to combinations, pharmaceutical compositions and fusion molecules comprising an FGF21 (fibroblast growth factor 21) compound and a GLP-1R (glucagon-like peptide-1 receptor) agonist with optimized GLP-1R agonist/FGF21 compound activity ratio. It further relates to their use as medicaments, in particular for the treatment of obesity, being overweight, metabolic syndrome, diabetes mellitus, diabetic retinopathy, hyperglycemia, dyslipidemia, Non-Alcoholic SteatoHepatitis (NASH) and/or atherosclerosis.
Public/Granted literature
- US20180236037A1 FGF21 COMPOUND / GLP-1R AGONIST COMBINATIONS WITH OPTIMIZED ACTIVITY RATIO Public/Granted day:2018-08-23
Information query
IPC分类:
